Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

481
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

22
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
22
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

5.7K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.

Gynecologic oncology·2026
Same author

Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.

The New England journal of medicine·2026
Same author

Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.

Scientific reports·2026
Same author

Single-cell and spatial detection of senescent cells using DeepScence.

Cell genomics·2025
Same author

Pilot Exploratory Analysis of Serum Gonadal Hormones, Inflammatory Proteins, and Intracerebral Hemorrhage Outcomes.

International journal of molecular sciences·2025
Same author

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Related Experiment Video

Updated: Aug 14, 2025

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.1K

Circulating Angiokines Are Associated With Reverse Remodeling and Outcomes in Chronic Heart Failure.

Josephine Harrington1, Andrew B Nixon2, Melissa A Daubert1

  • 1Department of Medicine, Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC.

Journal of Cardiac Failure
|January 12, 2023
PubMed
Summary

Circulating endothelial function markers like angiopoietin 2 (ANGPT2), VEGFR1, and HGF are linked to heart failure with reduced ejection fraction (HFrEF) progression and outcomes. Lower levels may indicate improved cardiac function and reduced risk in HFrEF patients.

More Related Videos

Murine Spinotrapezius Model to Assess the Impact of Arteriolar Ligation on Microvascular Function and Remodeling
16:43

Murine Spinotrapezius Model to Assess the Impact of Arteriolar Ligation on Microvascular Function and Remodeling

Published on: March 3, 2013

12.3K
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.5K

Related Experiment Videos

Last Updated: Aug 14, 2025

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.1K
Murine Spinotrapezius Model to Assess the Impact of Arteriolar Ligation on Microvascular Function and Remodeling
16:43

Murine Spinotrapezius Model to Assess the Impact of Arteriolar Ligation on Microvascular Function and Remodeling

Published on: March 3, 2013

12.3K
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.5K

Area of Science:

  • Cardiovascular Medicine
  • Biomarkers
  • Endothelial Function

Background:

  • Heart failure with reduced ejection fraction (HFrEF) is a complex condition.
  • Endothelial dysfunction is implicated in cardiovascular disease progression.

Purpose of the Study:

  • To investigate the association between circulating endothelial function modifiers and cardiac structure/clinical outcomes in HFrEF patients.

Main Methods:

  • Measured 25 endothelial function proteins in 99 GUIDE-IT study patients.
  • Assessed protein associations with echocardiographic parameters and clinical endpoints (death, heart failure hospitalization).

Main Results:

  • Higher angiopoietin 2 (ANGPT2), VEGFR1, and hepatocyte growth factor (HGF) correlated with worse cardiac function and larger volumes.
  • Decreases in ANGPT2, VEGFR1, and HGF over time linked to improved cardiac metrics.
  • Elevated ANGPT2, VEGFR1, or HGF increased 1-year risk for death or heart failure hospitalization.

Conclusions:

  • Endothelial function proteins are associated with cardiac structure, function, and outcomes in HFrEF.
  • These findings suggest endothelial function plays a role in HFrEF progression and recovery.